Dopamine: The Forgotten Felon in Type 2 Diabetes

E-ISSN： 2212-3334|5|1|61-65

ISSN： 1872-2148

Source： Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, Vol.5, Iss.1, 2011-01, pp. : 61-65

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Sitagliptin and Vildagliptin: Efficacy of Therapy in Type 2 Diabetes

Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, Vol. 2, Iss. 3, 2008-11 ,pp. : 162-171

Bentham Science Publishers

Access to resources Recommend Favorite

Hypoglycemic Agents in the Management of Type 2 Diabetes Mellitus

Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, Vol. 5, Iss. 1, 2011-01 ,pp. : 66-73

Bentham Science Publishers

Access to resources Recommend Favorite

GLP-1 as a Therapeutic Agent in Patients with Type 2 Diabetes Mellitus

Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, Vol. 1, Iss. 3, 2007-11 ,pp. : 193-201

Bentham Science Publishers

Access to resources Recommend Favorite

Biphasic (Premix) Insulin Analogs in Type 2 Diabetes Mellitus

Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, Vol. 2, Iss. 2, 2008-06 ,pp. : 129-134

Bentham Science Publishers

Access to resources Recommend Favorite

Diabetes Mellitus Type 2 and Functional Foods of Plant Origin

Recent Patents on Biotechnology, Vol. 8, Iss. 2, 2014-08 ,pp. : 160-164

Bentham Science Publishers

Access to resources Recommend Favorite